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Background: Acute ischemic stroke (AIS) occurs due to obstructed blood flow 
into blood vessels to the brain and is considered a medical emergency.  Thrombolytic 
therapy is the mainstay of AIS's acute management due to its benefit in improving 
neurological function within three months.  Alteplase is a tPA approved for the treatment 
of AIS and is widely studied.  Tenecteplase is another tPA approved for the treatment of 
Acute Myocardial Infarction (AMI) but not AIS.  Although tenecteplase is not FDA-
approved for AIS, it has theoretical advantages over alteplase, such as cost savings.  
Methods: Estimated cost savings in the form of avoided costs due to a reduction in 
hospital days, ICU days, emergency department (ED) visits and tPA costs as a consequence 
of moving from the current standard of care (SoC), alteplase, to the new drug scenario, 




Results:  A total of 336 patients received alteplase (n = 166) or tenecteplase (n = 
170) between August 2018 to August 2020.  There was no significant difference in the 
hospital, ICU, inpatient and emergency department (ED) length of stay between the 
tenecteplase and alteplase groups.  The estimated annual savings to Ascension for 
switching from tenecteplase to alteplase for the management of AIS was $563,001.  The 
cost per patient was lower for patients treated with tenecteplase ($9,969) then alteplase 
($13,054), resulting in a savings of $3,065 per patient. 
Conclusions: Tenecteplase is less expensive, easier to dose and administer, and 
may have less adverse events such as bleeding complications than alteplase. Thus, hospitals 
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Chapter 1: Introduction 
BACKGROUND 
Acute ischemic stroke (AIS) occurs due to obstructed blood flow into blood vessels 
to the brain and is considered a medical emergency.1  In the U.S., the prevalence of AIS is 
3% of adults, or about 7 million Americans.  Approximately 800,000 primary (first-time) 
and secondary (recurrent) strokes occur each year in the United States (U.S.), with roughly 
75% being primary strokes. Of those who suffer from a primary stroke, approximately 87% 
are ischemic infarctions caused by blocked blood vessels, 10% are intracerebral 
hemorrhages caused by bleeding inside the brain, and 3% are subarachnoid hemorrhages 
caused by bleeding in the area that surrounds the brain.2   
Several modifiable and non-modifiable risk factors apply to primary and secondary 
stroke.   Modifiable risk factors can be managed.  People with modifiable risk factors are 
at a low risk of stroke, since these can be changed with lifestyle modifications, or controlled 
with medical management.2 Non-modifiable risk factors, which cannot be controlled or 
changed, put patients at a high risk of stroke.2 Several major modifiable risk factors for 
AIS include hypertension, hyperlipidemia, diabetes mellitus, tobacco use, as well as 
antithrombotic therapy.  Management of these risk factors helps prevent primary and 
secondary strokes.3 Non-modifiable risk factors include age, sex, and race.2 For example, 
stroke is 24% to 30% higher in men.2  Individuals of Asian, African, and Latin American 
descent tend to have a higher frequency of stroke than those of European descent.  Lastly, 
the incidence of stroke rapidly increases with age, doubling for each decade after the age 
of 55 years.2 
The Food and Drug Administration approved the recombinant tissue-type 
plasminogen activator (tPA), alteplase, for AIS in 1996.  It is the only FDA-approved 
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thrombolytic therapy for AIS in the U.S.  Alteplase is an efficacious treatment for stroke 
and has been shown to improve outcomes.4  Its safety and efficacy is reviewed in more 
detail later in this chapter.  Additionally, significant emphasis is placed on early evaluation 
and thrombolysis with alteplase for the management of AIS.  Delays in starting the infusion 
in the setting of AIS may result in lower serum concentrations, which could decrease 
thrombolysis effectiveness, leading to poor outcomes.5  As a result, poor outcomes may 
increase health care costs to the patient and the health care system. 
AMERICAN HEART ASSOCIATION (AHA) AIS GUIDELINES  
Thrombolytic therapy is the mainstay of acute management for AIS due to its 
benefit in improving neurological function within three months.  The American Heart 
Association (AHA) recommends intravenous (IV) alteplase for eligible patients with mild 
but disabling stroke symptoms who can be treated within 3 hours of symptom onset (COR: 
I; LOE: BR; Table 1.1).  Intravenous alteplase may also be reasonable for patients treated 
within 3 to 4.5 hours of symptom onset.  For severe stroke, IV alteplase is indicated within 
3 hours of symptom onset.6   
Although IV alteplase is recommended for the treatment of AIS, it is not 
recommended in some patients, including those with a mild non-disabling stroke even if 
they are within the recommended time window of 0 to 3 hours or 3 to 4.5 hours.  It also 
should not be administered to patients with an active intracranial hemorrhage or a history 
of an intracranial hemorrhage or subarachnoid bleeding.  Additionally, patients should not 
receive alteplase if they have had intracranial or intraspinal surgery, ischemic stroke, or 
severe head trauma within the last three months.6 
The 2019 AHA Guidelines for management of AIS also state that it may be 
reasonable to choose IV tenecteplase (single IV bolus of 0.25 mg/kg, maximum 25 mg) 
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over IV alteplase in patients without contraindications for IV fibrinolysis (COR: IIb; LOE: 
B-R).  The guidelines also recommend considering IV tenecteplase, administered as a 0.4 
mg/kg single IV bolus, as an alternative to alteplase in patients with minor neurological 
impairment and no major intracranial occlusion (COR: I; LOE: B-R).  This dose has not 
been shown to be superior or non-inferior to alteplase.6 
 
Table 1.1 Treatment of AIS: IV Administration on Alteplase6 
Infuse 0.9 mg/kg (maximum dose 90 mg) over 60 min, with 10% of the dose given as a 
bolus over 1 min. 
Admit the patient to an intensive care or stroke unit for monitoring. 
If the patient develops severe headache, acute hypertension, nausea, or vomiting or has 
a worsening neurological examination, discontinue the infusion (if IV alteplase is being 
administered) and obtain emergency head CT scan. 
Measure BP and perform neurological assessments every 15 minutes during and after IV 
alteplase infusion for 2 hours, then every 30 minutes for 6 hours, then hourly until 24 
hours after IV alteplase treatment. 
Increase the frequency of BP measurements if SBP is > 180 mmHg or if DBP is > 105 
mmHg; administer antihypertensive medications to maintain BP at or below these levels. 
Delay placement of nasogastric tubes, indwelling bladder catheters, or intraarterial 
pressure catheters if the patient can be safely managed without them. 
Obtain a follow-up CT or MRI scan at 24 hours after IV alteplase before starting 
anticoagulants or antiplatelet therapy.  
BP – Blood Pressure; SBP – Systolic Blood Pressure; DBP = Diastolic Blood Pressure; CT – computed tomography; 
MRI – Magnetic resonance imaging  
 
IV ALTEPLASE: SAFETY AND EFFICACY IN THE SETTING OF AIS 
Alteplase is a tPA approved for the treatment of AIS.  When introduced into 
systemic circulation at recommended doses, it binds to fibrin in a thrombus and converts 
the entrapped plasminogen to plasmin.  This initiates local fibrinolysis.  However, the 
conversion of plasminogen is limited in the absence of fibrin.  Alteplase rapidly clears from 
the plasma with an initial half-life of fewer than 5 minutes.  The most common side effect 
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of alteplase is bleeding.  In clinical studies in patients with AIS, intracranial hemorrhage 
was higher in the alteplase treated group than in the placebo group.  A dose-finding study 
suggested that doses greater than 0.9 mg/kg may be associated with an increased incidence 
of intracranial hemorrhage.7 
Alteplase in the setting of AIS has been widely studied.  Two placebo-controlled, 
double-blinded trials in patients with AIS led to the  approval of alteplase in the U.S.  Both 
studies enrolled patients with neurological deficient who could complete screening and 
begin study treatment within 3 hours from symptoms onset. Patients were randomized 1:1 
to either the alteplase (0.9 mg/kg) or placebo group.  Alteplase was administered as a 10% 
initial IV bolus over 1 minute, followed by the reminding dose administered as continuous 
IV infusion over 60 minutes.7 
The first study enrolled 291 patients and evaluated neurological improvement at 24 
hours after stroke onset.  The primary endpoint was the proportion of patients with 4 points 
or greater improvement in the National Institutes of Health Stroke Scale (NIHSS) score or 
complete recovery. The level of stroke severity measured by the NIHSS system is no stroke 
(score of 0), minor stroke (score between 1 and 4), moderate stroke (score between 5 and 
15), moderate to severe stroke (score between 15 to 20) and severe stroke (21 to 42).  There 
was not a significant difference in the primary outcome between the treatment groups.7 
The second study enrolled 333 patients and assessed clinical outcomes at three 
months.  A favorable outcome (defined per scale in parenthesis) was defined as minimal 
or no disability using four stroke assessment scales:  the Barthel Index (score of 95 or 
greater), the Modified Rankin Scale (score of 1 or less), the Glasgow Outcome Scale (score 
of 1), and the NIHSS (score of 1 or less).  The results comparing alteplase and placebo-
treated patients for the four outcomes together and individually are presented in Table 1.2.   
Depending on the scale, the favorable outcome of minimal or no disability occurred in at 
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least 11 per 100 more patients treated with alteplase than those receiving placebo.  Study 
results demonstrated functional and neurological improvement within all four stroke 
scales.7 
Lastly, alteplase is contraindicated in situations where the risk of bleeding is greater 
than the potential benefit.  These situations include current intracranial hemorrhage, 
subarachnoid hemorrhage, active internal bleeding, intracranial or intraspinal surgery, 
severe head trauma within the past three months, presence of intracranial conditions that 
may increase the risk of bleeding, bleeding diathesis, and current severe uncontrolled 
hypertension.7 
 
Table 1.2.  Study 2 Efficacy Outcomes at Three-Months7 
 







































a. Favorable outcome is defined as recovery with minimal or no disability 
b. Value greater than 1 indicates odds of recover in favor of alteplase treatment  
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SHORTCOMINGS OF IV ALTEPLASE 
Shortcomings of IV alteplase include delayed drug administration, dosing errors, 
and an increased risk of bleeding.  Another drawback is the lack of appropriately trained 
or certified staff needed to correctly administer alteplase.  
Due to alteplase's short half-life, a loading dose followed by continuous infusion is 
necessary to achieve adequate concentrations. Delays in drug administration are a concern 
with the alteplase dosing regimen.  Delays result in lower serum concentrations, which can 
have a subsequent effect on clinical outcomes.  One study investigated delays in alteplase 
administration and the effect on serum plasma concentrations of alteplase.  It determined 
that administration of alteplase infusion > 5 minutes after initial bolus dose resulted in 
significantly decreased serum plasma concentrations of alteplase and concluded that 
alteplase infusion should be given immediately after the initial bolus does to maintain 
therapeutic plasma concentrations.8 A second study conducted by Acheampong et al. 
observed the clinical outcomes associated with delays in alteplase bolus dose and 
continuous infusion.  The study found that an infusion delays of > 8 minutes resulted in 
lower independent functional outcomes and higher mortality but the difference was not 
statistically significant, likely due to the small sample size.9  
Additionally, dosing errors related to alteplase therapy for the management of AIS 
are documented in literature.  The primary reason for dosing errors of alteplase is inaccurate 
weight records (recall that alteplase is dosed by weight).  A single-center retrospective 
study found that the majority of patients evaluated had estimated weights used to dose 
alteplase.  These patients were more likely to be obese, older, have impaired consciousness 
on admission, and have a longer door to needle times.10  Another observational study based 
on a  retrospective chart review also found that most patients who received alteplase were 
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dosed based on estimated weights, concluding that patients who were not weighed in the 
hospital had significantly greater NIHSS scores on admission and increased mortality.11  
While alteplase has been shown to benefit some patients who presented with acute 
stroke symptoms within 4.5 hours, its administration increases the patients’ risk of 
intracranial hemorrhage.  The PRISMS trial was terminated before reaching its enrollment 
goals. However, it found that alteplase treatment did not improve neurologic outcomes at 
90 days compared to aspirin for minor strokes.11 Additionally, a study by Wee et al. found 
no benefit in administering alteplase to patients undergoing endovascular thrombectomy 
for acute stroke due to larger vessel occlusion as compared to thrombectomy alone.11  
However, this was based on a small sample of patients.   
Lastly, many tertiary care facilities involve trained clinical pharmacists in stroke 
protocols.  It has been shown that the involvement of a clinical pharmacist has reduced 
door-to-needle time significantly in the setting of AIS.12  However, staffing of clinical 
pharmacists may not be feasible in smaller or rural hospitals.  Also, the alteplase drip 
administration requires an IV pump, which not all emergency medical technicians are 
qualified to manage.  This can cause a delay in dosing or complicate a patient’s interfacility 
transfer.12 
TENECTEPLASE FOR THE MANAGEMENT OF AIS 
Tenecteplase is a tPA that has been approved for the treatment of Acute Myocardial 
Infarction (AMI), but not AIS.  Currently, tenecteplase is undergoing a pilot evaluation as 
part of a study funded by the National Institutes of Health for AIS.13  Although tenecteplase 
is not FDA-approved for AIS, it has theoretical advantages over alteplase.  For example, it 
has greater fibrin specificity and a longer half-life than alteplase..14  These pharmacologic 
differences allow tenecteplase to be administered as a bolus rather than a bolus followed 
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by continuous infusion.  It should be noted that current evidence suggests that 0.25 mg/kg 
(maximum dose of 25 mg) is the optimal dose.  Additionally, the use of tenecteplase does 
not require a pump, which would simplify the administration of thrombolytics. 
Lastly, because the human nervous tissue is rapidly lost as stroke progresses there 
is a great deal of emphasis on achieving rapid door-to-needle times for thrombolytics. 
However,  although the door-to-thrombolytic initiation time is important, and is generally 
tracked as a quality measure, the door-to-thrombolytic completion time may be more 
important to assess.12 A patient who is given tenecteplase will have a one-hour faster door-
to-thrombolytic completion time than if they were given alteplase.12 
EFFICACY-  IV TENECTEPLASE COMPARED WITH IV ALTEPLASE AFTER AIS 
Five randomized controlled trials compared IV alteplase and IV tenecteplase for 
use in acute ischemic stroke.  These studies evaluated improvements in neurologic function 
after an AIS. 
In 2010, Haley et al. published results from a small, multicenter, randomized, 
double-blind trial of 112 patients with AIS within 3 hours of symptoms onset.  They 
compared tenecteplase 0.1 milligrams per kilogram (mg/kg), tenecteplase 0.25 mg/kg, 
tenecteplase 0.4mg/kg, to standard-dose alteplase (0.9 mg/kg).  The trial was terminated 
because of slow enrollment.  Patients in the tenecteplase 0.4 mg/kg group had the lowest 
rate of good neurological outcomes at three months.  There were no statistically significant 
differences among the other groups, but there was a trend towards higher percentages of 
patients having good neurologic outcomes in the tenecteplase 0.1 mg/kg (45.2%) and 0.25 
mg/kg (48.4%) groups as compared to the alteplase group (41.9%).15  
In 2012, Parsons et al. published a study that randomized 75 patients with AIS less 
than six hours after onset of symptoms to tenecteplase 0.1 mg/kg, tenecteplase 0.25 mg/kg, 
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or standard-dose alteplase.  Twenty-five patients were enrolled in each group.  Patients 
treated with tenecteplase had significantly greater reperfusion on imaging studies and 
clinical improvement (P <0.001) at 24 hours than the alteplase treated group. The higher 
dose of tenecteplase, in this case, the 0.25 mg/kg dose, had superior outcomes compared 
to those receiving alteplase for all efficacy outcomes, including serious disability, at 90 
days (72 % vs. 40% with alteplase, P = 0.02).16   
In 2015, Huang et al. published the results from a single-center, phase 2, 
prospective, randomized trial that compared tenecteplase 0.25 mg/kg to standard-dose 
alteplase for patients with AIS within 4.5 hours of symptom onset.  A total of 104 patients 
were enrolled, with 52 assigned to each group.  There was no difference between groups 
regarding the primary outcome of percentage penumbra salvaged, 68% in each group.  
Brain cells within the penumbra, a rim of mild to moderately ischemic tissue lying between 
tissue that is normally perfused and the area in which infarction is evolving, may remain 
viable for several hours but can die of reperfusion if not established during the early hours 
of symptom onset.19   There were also no significant differences in secondary outcomes 
between groups. Still, the tenecteplase groups tended towards more early neurologic 
improvement at 24 hours (40% vs. 24%) and a higher percentage of good neurologic 
outcomes at 90 days (28% vs. 20%).18 
In 2017, Logallo et al. published the results from a block-randomized study 
comparing tenecteplase 0.4 mg/kg and standard-dose alteplase for patients with suspected 
AIS within 4.5 hours or less of symptom onset or within 4.5 hours of awakening with 
symptoms.  A total of 549 patients were randomized to the tenecteplase group, and 551 
were randomized to the alteplase group.  There were no differences between groups in the 
primary outcome of good neurologic outcome at 90 days (64% tenecteplase vs. 63% 
alteplase.19 The primary outcome was excellent (0-1points) functional outcomes at 3 
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months measured by modified Rankin Scale (mRS).  The mRS is used to measure the 
degree of disability in patients how have had a stroke, where a score of 0 means no 
symptoms at all and a score of 1 means no significant disability despite symptoms and the 
patient is able to carry out all usual duties and activities. 
In 2018, Campbell et al. compared tenecteplase 0.25 mg/kg to standard-dose 
alteplase for patients with AIS symptoms for less than 4.5 hours before thrombectomy.  
There were 101 patients in each group.  There was a statistically significant difference 
between groups regarding the primary outcome of reperfusion of greater than 50% of the 
involved ischemic territory or an absence of retrievable thrombus at the time of the initial 
angiographic assessment.  This primary outcome was found in 22% of patients in the 
tenecteplase group as compared to 10% of those with alteplase.  Patients in the tenecteplase 
also had superior functional neurologic outcomes at 90 days as compared to the alteplase 
group.20   
Four meta-analyses have been conducted using the clinical trials described above.  
All of these meta-analyses reported no statistically significant differences regarding 
neurologic recovery, and none of the meta-analyses found a difference between 
tenecteplase and alteplase with regards to mortality.23-26  However, the meta-analyses by 
Thelengana et al. and Kheiri et al. reported scientifically improved early neurologic 
improvement with tenecteplase22,23  
In summary, five randomized controlled trials have found tenecteplase to be at least 
as effective or more effective than alteplase for neurologic improvement after acute 
ischemic stroke.  Using the results of those five randomized controlled trials, four separate 
meta-analyses have been performed, and none of them concluded that alteplase is superior 
to tenecteplase.   
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SAFETY-  IV TENECTEPLASE COMPARED WITH IV ALTEPLASE AFTER AIS 
In addition to efficacy, the clinical trials described above also measured the rates of 
symptomatic and total intracerebral hemorrhage.  Neither of the most recent meta-analysis 
found statistically significant differences in intracerebral hemorrhage rates between 
tenecteplase and alteplase, but there were trends toward less intracerebral hemorrhage with 
tenecteplase (OR 0.81; 95% CI 056 -1.17; p=0.26).25  However, there is evidence that the 
0.4 mg/kg dose of tenecteplase might lead to higher intracerebral hemorrhage rates 
compared to the preferred 0.25 mg/kg dose. 
Considering other adverse bleeding events associated with the administration of 
alteplase and tenecteplase. Three randomized controlled trials compared tenecteplase to 
alteplase for patients with acute coronary syndrome and reported major bleeding adverse 
events.26-28  The assumption made here is that adverse events in patients with acute 
coronary syndrome are likely to be similar in patients diagnosed with AIS.  The ASSENT-
2 trial, which randomly assigned patients with acute myocardial infarction to alteplase or 
tenecteplase, found that patients who received tenecteplase had reduced rates of non-
cerebral bleeding complications (26.43 vs. 28.95%, p= 0.0003).26  A meta-analysis that 
included the ASSENT-2 trial and studies by Liang et al. and Binbrek et al. included 17,325 
patients and found a statistically significant reduction in major bleeding with tenecteplase 
as compared with alteplase (RR 0.79; 95% CI 0.69-0.90; p=0.0002).27-29   
In summary, no statically significant difference has been reported in the available 
literature in the rates of intracerebral hemorrhage for tenecteplase versus alteplase in 
patients diagnosed with AIS.  The use of tenecteplase was also associated with lower rates 
of non-cerebral bleeding than alteplase. 
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COST-  IV TENECTEPLASE COMPARED WITH IV ALTEPLASE AFTER AIS 
AIS contributes to a large health care burden, accounting for 87% of all strokes, 
with an estimated 700,000 events annually, in the U.S..  This costs an estimated $22.8 
billion in direct health care expenditures in the U.S. annually.  By 2030, the direct health 
care costs are projected to grow to $18 billion.30 Health care costs will continue to rise, and 
changing the way care is delivered to AIS patients is critical to mitigating financial outlays.   
 
The usual dose of tenecteplase is less expensive than the usual dose of alteplase, 
both nationally and internationally, with one study from Nepal stating that alteplase is 
twice as expensive as tenecteplase ($450 for tenecteplase versus $1000 for alteplase).31  
According to Lexicomp (2021), in the United States, a 50 mg vial of tenecteplase costs 
$7,500, while a 100 mg vial of alteplase costs $10,500.32 Given the doses of 0.25 mg up 
to 25 mg for tenecteplase and 0.9 mg/kg up to 90 mg for alteplase, it is evident that 
tenecteplase is the less expensive of the two tPAs.33  
STUDY RATIONALE 
Due to the evidence described above and the ease of administration of tenecteplase 
compared to alteplase, Ascension Texas facilities transitioned from alteplase to 
tenecteplase as the thrombolytic drug of choice for AIS management in September 2019.  
In addition to the safety and effectiveness of tenecteplase in AIS, it is also important to 
consider cost savings implications to a hospital system for using tenecteplase in place of 
alteplase for patients with AIS.
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Chapter 2: Methodology 
COST SAVINGS ANALYSIS 
Study Objectives and Hypothesis 
The aim of this study was to estimate the cost savings associated with the use of 
tenecteplase compared to alteplase in patients with AIS.  The analysis focused on cost 
savings associated with the following endpoints: (1) Total Hospital days; (2) Intensive Care 
Unit (ICU) days; (3) Non-ICU hospital days (4) Emergency Department (ED) visits, and 
(5) Medication costs of tPAs.  
The specific null hypotheses of these analyses included: 
• H01.1: The difference in costs avoided for total hospital days between alteplase 
and tenecteplase cohorts is not statistically significant. 
• H01.2: The difference in costs avoided for ICU days between alteplase and 
tenecteplase cohorts is not statistically significant. 
• H01.3: The difference in costs avoided for Non-ICU days between alteplase and 
tenecteplase cohorts is not statistically significant. 
• H01.4: The difference in costs avoided for ED visits between alteplase and 
tenecteplase cohorts is not statistically significant. 
• H01.5: The difference in costs avoided for medication costs of tPAs between 
alteplase and tenecteplase cohorts is not statistically significant. 
 
Study Design 
  Cost savings were estimated in the form of avoided costs for total hospital days, 
ICU days, Non-ICU days, emergency department (ED) visits and medication of tPA as a 
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consequence of moving from the current standard of care (SoC), alteplase to the new drug 
scenario, tenecteplase in the setting of AIS. 
 The analysis compared costs between two cohorts of patients at Ascension Texas 
facilities.  The first cohort consisted of patients who were diagnosed with AIS and who 
were eligible to receive alteplase for AIS between September 1, 2018 and August 31,. 2019.  
The second cohort was made up of patients who were diagnosed with AIS and who 
received tenecteplase for AIS between September 1, 2019 and August 31, 2020.  The same 
eligibility criteria were applied to both alteplase and tenecteplase per Ascension’s AIS 
protocol.  Patients were eligible to receive tenecteplase or alteplase within 4.5 hours of AIS 
symptom onset, but preferably within 3 hours of symptom onset.  Patients with a greater 
risk of bleeding than potential benefits were not eligible to receive either therapy to treat 
acute ischemic stroke.  These patients included those with current intracranial hemorrhage 
(ICH); subarachnoid hemorrhage; active internal bleeding; recent (within three months) 
intracranial or intraspinal surgery or serious head trauma; the presence of intracranial 
conditions that may increase the risk of bleeding (e.g., some neoplasms, arteriovenous 
malformations, or aneurysms); bleeding diathesis; or current severe uncontrolled 
hypertension.  Subjects were excluded if they did not receive either medication or did not 




Outcomes Measured, Definitions, & Data Source 
 
Outcomes and their definitions are found in Table 2.1.  The data source for all 
outcomes measured was Ascension’s electronic medical record (EMR) data.  Index 
hospitalizations were defined as the encounter in which the patient was diagnosed with an 
acute ischemic stroke and received alteplase or tenecteplase.  Hospital readmissions were 
defined as any inpatient stay within 30 or 60 days after the index hospitalization discharge 
date. Costs estimates per unit of utilization were estimated from previously published 
literature.  Costs were adjusted to 2021 US dollars using the Medical CPI index for all cost 
except medication costs.  Medication costs were reported in 2021 prices.   
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Outcomes measured Definition 
Readmissions avoided  The change in the readmission rate at 30 and 60 days from the 
discharge date of the index admissions, calculated by subtracting the 
percentage of patients who were readmitted in the tenecteplase group 
from the percentage readmitted in the alteplase group.   
Inpatient Hospital 
Days Avoided 
The change in the inpatient hospital days, calculated by subtracting the 
average number of inpatient hospital days for patients in the 
tenecteplase group from the average number of inpatient hospital days 
in the alteplase group 
ICU Days Avoided The change in ICU days, calculated by subtracting the average number 
of ICU days for patients in the tenecteplase group from the average 




The change in non-ICU days, calculated by subtracting the average 
number of non-ICU days for patients in the tenecteplase group from the 





The change in ED hours, calculated by subtracting the average number 
of ED hours for patients in the tenecteplase group from the average 
number of ED hours in the alteplase group 
Index Admission 
Costs 
The sum of all costs accrued by the patient for the index admission, 
which includes inpatient, emergency department, and medication costs. 
ICU- Intensive Care Unit; ED – Emergency Department 
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Costs Definitions, Data Sources, and Estimates 
Cost definitions and data sources are found in Table 2.2. Estimates of each unit costs are 
found in Table 2.3. 
Table 2.2. Costs Saving Analysis - Costs Definitions and Data Sources  
Costs  Definition  Data Source 
Average Total 
Inpatient Cost 
The sum of all costs accrued by the 
patient while admitted for an 
inpatient stay, divided by the number 
of patients. Sum of  ICU and non-
ICU costs.  
Simpson et al. 201234 
Kramer et al. 201735 
Average ICU Cost The sum of all costs accrued by the 
patient while admitted in the ICU, 
divided by the number of patients.  
Used to estimate total healthcare 
costs for the encounter.   
Kramer et al. 201735 
Average Non-ICU 
Cost 
The sum of all costs accrued by the 
patient while admitted in the non- 
ICU, divided by the number of 
patients.  Used to estimate total 
healthcare costs for the encounter. 





The sum of all costs accrued by the 
patient while admitted in the ED, 
divided by the number of patients.  
Used to estimate total healthcare 
costs for the encounter. 
Simpson et al. 201234 
Average Medication 
Costs 
The sum of all tPA costs accrued by 
the patient while admitted for an 
inpatient stay, divided by the number 
of patients.  Used to estimate total 
healthcare costs for the encounter. 
Red Book (AWP, 2021)36 
Total Health Care 
Cost 
The sum of all costs accrued by the 
patient for the index admission, 
which includes inpatient, emergency 
department, and medication costs, 
divided by the number of patients   





Table 2.3. Costs Saving Analysis - Costs Estimates for Inputs 
Cost Input Tenecteplase ($) Alteplase ($) 
Tenecteplase (50 mg vial; 
2021)36 
$7,462.63 Not applicable 
Alteplase (100 mg vial; 2021)36 Not applicable $10,560.43 
Hospital, cost per event -adjusted to 2021 costs 
Non-ICU day34 $4,699,16 
ICU day35 $18,969.48 
ED Visit34 $1,951.12 
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STATISTICAL ANALYSIS FOR COST SAVINGS ANALYSIS 
Descriptive statistics were performed with continuous variables described using 
means with standard deviations (SD) or medians with interquartile ranges (IQR) and 
categorical variables described in frequency with percentages.  An α <0.05 was used as the 
threshold for statistical significance. Data processing, cleaning, and analysis were 
conducted using Microsoft Excel.  This study was approved by the Institutional Review 
Boards of the University of Texas and Ascension. 
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Chapter 3: Results  
OVERVIEW  
Based on the EMR records for Ascension‘s Texas facilities,  166 patients received 
alteplase between September 1, 2018 and August 31, 2019, while 170 patients received 
tenecteplase between September 1,  2019 and August 31, 2020. 
DEMOGRAPHICS 
The demographic characteristics for the population under study are depicted in 
Table 3.1.  The mean (standard deviation, SD) age of the tenecteplase cohort was 65 years 
(SD 16) and 59% were male.  The mean (SD) age of the alteplase cohort was 66 years (18 
SD), and 54% were male.  A majority of patients who received tenecteplase (62%) and 
alteplase (66%) were white.  With respect to insurance type, almost half of patients in the 
tenecteplase cohort (48%) were Medicare beneficiaries, where less in the alteplase cohort 
(41%) were Medicare beneficiaries.   
As expected, hypertension, dyslipidemia, diabetes, and obesity/overweight 
diagnoses were the four leading comorbid conditions for both populations (Table 3.1).  
Additionally, 15% and 16% of patients in the tenecteplase and alteplase cohorts, 




Table 3.1 Patient Demographic Characteristics by Anti-thrombolytic Therapy 
 
Alteplase 
N = 166 
Tenecteplase 
N = 170 
Age (years) , Mean (SD) 66 (18) 65 (16) 
Gender, n (%) 
Female 77 (46) 70 (41) 
Male 89 (54) 100 (59) 
Race, n (%) 
White 110 (66) 106 (62) 
Black 23 (14) 13 (8) 
Asian 2 (1) 1 (1) 
American Indian 0 (0) 1 (1) 
Other 32 (19) 49 (29) 
Insurance Type, n (%) 
Medicare 68 (41) 81 (48) 
Non-Medicare 73 (44) 62 (36) 
Missing 25 (15) 27 (16) 
Comorbidities, n (%) 
Dyslipidemia 62 (37) 97 (57) 
Family History of Stroke 10 (6) 20 (12) 
Obesity/Overweight 55 (33) 90 (53) 
Diabetes 40 (24) 66 (39) 
CAD 28 (17) 32 (19) 
Prior MI 26 (16) 26 (15) 
Afib/flutter 32 (19) 29 (17) 
Heart Failure 15 (9) 13 (8) 
Renal insufficiency 9 (5) 10 (6) 
Dementia 0 (0) 5 (3) 
Hypertension 101 (61) 107 (63) 
Smoker 21 (13) 29 (17) 
Depression 17 (10) 23 (14) 
Drug/Alcohol Abuse 11 (7) 14 (8) 
Previous Stroke 37 (22) 39 (23) 
 
RE-ADMISSION, THROMBECTOMY, AND DISCHARGE DISPOSITION 
With respect to readmissions, 9% of patients were readmitted within the first 30 
days and 4% were readmitted within 60 days after discharge in the tenecteplase group.  In 
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the alteplase group, 8% of patients were readmitted within the first 30 and 1% were 
readmitted within 60 days after discharge. (Table 3.2) 
With respect to discharge disposition associated with the primary admission, a 
majority of patients were discharged home in the tenecteplase (40%) and alteplase (43%) 
cohorts, followed by discharge to another health care facility (34% and 33%, respectively) 
or acute care facility (21% and 18%, respectively). (Table 3.2) 
A small proportion of patients who were admitted for AIS received a thrombectomy 
during the primary admission for the tenecteplase cohort (15%) and the alteplase cohort 
(16%).  Primary admission is defined as the admission in which the patient was diagnosed 
with AIS. (Table 3.2) 
Table 3.2: Thrombectomy, Re-admission, and Discharge Disposition 
 
Alteplase 
N = 166 
Tenecteplase 
N = 170 
Thrombectomy, n (%) 
Yes 27 (16) 25 (15) 
Re-admission, n (%) 
Re-admission (0-60 days) 16 (10) 22 (13) 
Re-admission (0-30 days) 14 (8) 16 (9) 
Re-admission (31-60 days) 2 (1) 6 (4) 
Discharge Disposition  
  
Home 71 (43) 68 (40) 
Hospice 2 (1) 4 (2) 
Acute Care Facility 30 (18) 36 (21) 
Other Health Care Facility 54 (33)  58 (34) 
Expired 8 (5) 3 (2) 
Left Against Medical Advice  2 (1) 1 (1) 
 
COST SAVINGS ANALYSIS 
There were no significant differences in the hospital, ICU, inpatient or emergency 
department (ED) length of stay between the tenecteplase and alteplase groups (Table 3.3).  
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Cost were calculated for each group.   The estimated annual savings to Ascension 
based on switching from tenecteplase to alteplase for the management of AIS was 
$563,001.  The cost per patient was lower for patients treated with tenecteplase ($9,969) 
then alteplase ($13,054).  The per patient savings is $3,086 (Table 3.4) almost entirely due 
to a reduction of medication costs. 
 
Table 3.3 Healthcare Utilization Outcomes 
3 
Alteplase 
N = 166 
Tenecteplase 
N = 170 P-value 
Hospital LOS Total days  
(mean, SD) 7.0 (5.4) 7.0 (5.7) 0.672 
     ICU LOS, days (mean, SD) 3.5 (3.7) 3.9 (4.3) 0.214 
     Non-ICU inpatient LOS,  
      days  (mean, SD) 3.6 (4.0) 3.1 (3.3) 0.287 
Emergency Department LOS, 
hours (mean, SD) 3.2 (1.7) 3.4 (1.6) 0.161 
Emergency Department visits, 
 n (%)  165 (99%) 168 (99%) - 
Vials used, n (%)  166 (100%) 170 (100%) - 
 












Hospital Cost Total $          84,371 $508 $          90,427 $532 $      6,056 
ICU Cost $          67,156 $405 $          75,286 $443 $      8,131 
     Non-ICU Inpatient               
Cost $          17,216 
$104 
$          15,141 
$89 
$     (2,075) 
Emergency Department 
Cost $        329,604 
  
$1,986 $        335,597 
 
$1,974 $      5,993 
tPA Medication Cost  $     1,753,031 $10,560 $     1,268,647 $7,463 $ (484,384) 




Chapter 4: Discussion 
Readmissions are common among AIS patients.  In this study, 8% to 9% of 
patients with AIS were readmitted within 30 days of the primary admission.  This is 
much lower than reported readmission rates by Johnson et al.39  Johnson et al. reported 
higher readmission rates of 25% and 39% within 30 days for commercial and Medicare 
patients, respectively.39  However, it should be noted that this study did not compare rates 
between tenecteplase and alteplase, only between Medicare and commercial beneficiaries 
diagnosed with AIS, it included all patients regardless of insurance status.    There could 
be many reasons for the difference in readmission between our study and that reported in 
Johnson et al.  First is that patients could have been readmitted to another health system 
and therefore they would not be captured in our study EMR database.  Second, is that 
Johnson et al. may have included more severely ill patients then the current study. 
Gao et al. estimated that the use of tenecteplase rather than alteplase across the 
United States for eligible large vessel stroke patients (69,165 patients per year) would save 
$366 million USD in acute hospital costs (including avoided thrombolysis and 
thrombectomy for the first 3 months), with an additional $435 million USD in savings over 
the lifetime.38  The current study demonstrated cost savings of tenecteplase over alteplase 
in patients with ischemic stroke.  This was almost entirely due to the reduction of tPA 
medication costs.  Tenecteplase at stroke dosage is less expensive than alteplase.  
Additionally, our study showed a non-significant reduction in thrombectomy procedures 
for the tenecteplase cohort versus the alteplase cohort (15% vs. 17%).  However, there may 
be cost savings associated with reduction in in thrombectomy in patients treated with 
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tenecteplase.  Gao et al. reported additional costs savings associated with a reduction in the 
requirement for thrombectomy procedure in 1 in 10 patients treated with tenecteplase over 
alteplase.38  
Although this study did not find any significant differences in units of health-care 
resource utilization, both short- and long-term health care resources utilization and costs 
associated with acute ischemic stroke have been reported elsewhere.  Johnson et al. 
reported mean all-cause costs for commercial and Medicare patients the year following an 
AIS were $61,354 and $44,929, respectively.41  A large share (50-55%) of these costs 
occurred more than 30 days after the index admissions.  During 31 to 365 days following 
the admission for AIS, costs were largely attributed to services delivered in the outpatient 
setting (83% - 85% for AIS related costs; commercial and Medicare, respectively).  The 
cost drivers were increased utilization of various outpatient services, such as outpatient 
hospital visits, office visits, and rehabilitative therapy.  Outpatient services were not 
incorporated in our study, but it is possible that similar cost savings would accrue.39    
LIMITATIONS  
This study had a number of limitations.  First, there may be additional costs 
associated with treatment of either alteplase or tenecteplase that were not included in this 
analysis, such as outpatient costs and administration costs.  Only costs during the index 
inpatient stay were included in this analysis.  Additionally, and as mentioned above, 
tenecteplase has greater fibrin specificity and a longer half-life than alteplase.  Due to these 
pharmacologic differences, tenecteplase is administered as a bolus, where alteplase is 
administer as a bolus followed by a continuous infusion.   Also, the administration of 
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alteplase requires an IV pump, as well as a nurse, technician or pharmacist who is qualified 
to manage IV pumps.  Therefore, the cost associated with the time to administer and to 
monitor may be different among each tPA and may result in additional costs.  This could 
possibly affect the estimated costs savings associated with the use of tenecteplase.  Second, 
national average costs for non – ICU days and ED visits were based on 2012 Medicare data 
and inflated to 2021 costs.   Third, the costs associated with the avoidance of a dosing error, 
incident of bleeding and/or recurring episode of stroke were not included in the analysis.  
Although the costs of treating adverse events could be similar between the two therapies, 
depending the on the incidence of bleeding, it is important to include the costs within the 
impact analysis for creditability purposes.  Additionally, any reimbursements offered by 
pharmaceutical manufacturers to the hospital system were not included in the benefit 





Chapter 5: Conclusion  
 Previous studies have shown that tenecteplase is as effective as alteplase with 
regards to neurologic improvement after treatment of acute ischemic stroke. Additionally, 
tenecteplase is less expensive, easier to dose and administer, and may have less adverse 
events such as bleeding complications than alteplase. Our study used real-world outcomes 
to estimate differences in healthcare utilization and costs between tenecteplase and 
alteplase cohorts and found that differences in health care utilization were small and not 
statistically significant, but costs were about $3,000 lower for the tenecteplase cohort, 
largely due to the lower cost of the tPA.  Thus, hospitals should consider using tenecteplase 
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